Soares Jordana de Paula, Najas Gabriel Faria, Mauro Geovanne Pedro, Lima Kennya Medeiros Lopes de Barros, Ramos Clarissa Cerchi Angotti, Araujo Pedro Henrique Xavier Nabuco de, Carvalho Heloisa de Andrade
. Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil.
. Instituto do Câncer do Estado de São Paulo - ICESP - Universidade de São Paulo, São Paulo (SP) Brasil.
J Bras Pneumol. 2025 Sep 8;51(3):e20240331. doi: 10.36416/1806-3756/e20240331. eCollection 2025.
Thymic tumors are a rare group of anterior mediastinal tumors. Surgery is the primary treatment. Adjuvant treatment is used in select cases. The purpose of this study was to evaluate the outcomes of patients with thymic tumors, submitted or not to radiotherapy, and identify risk factors that could impact the outcomes to better support patient selection for RT.
This is a single institution retrospective cohort study. Patients with histologically proven thymoma or thymic carcinoma treated from July of 2009 to November of 2020 were included. Analysis was based on the use of radiation therapy (RT). Overall survival and disease-free survival were assessed from the date of diagnosis. To minimize selection bias, propensity score matching (PSM) regression using Kernel matching was used, estimated on the population for average treatment effect.
Overall, 101 patients were analyzed, with mean age at diagnosis of 54.6 years (range 25-84 years). Unfavorable histology and more advanced stages predominated in the cohort. Nevertheless, most (69.3%) were treated with radical intent. RT was delivered in 52.9% of these patients. Five-year OS, local progression and distant progression free survivals were 81.0%, 95.0% and 88.1%, respectively for the radical intent cohort. PSM showed that RT reduced the chances of death by 6.3% (matched sample size was 60, p = 0.02).
In this retrospective cohort, RT had a positive impact in OS after PSM analysis. Prospective data regarding the role of RT in this disease is needed to validate these findings.
胸腺瘤是一组罕见的前纵隔肿瘤。手术是主要治疗方法。部分病例采用辅助治疗。本研究的目的是评估接受或未接受放疗的胸腺瘤患者的预后,并确定可能影响预后的危险因素,以更好地支持放疗患者的选择。
这是一项单机构回顾性队列研究。纳入2009年7月至2020年11月期间经组织学证实为胸腺瘤或胸腺癌的患者。分析基于放疗(RT)的使用情况。从诊断日期开始评估总生存期和无病生存期。为尽量减少选择偏倚,采用核匹配的倾向评分匹配(PSM)回归,对总体平均治疗效果进行估计。
总体上,分析了101例患者,诊断时的平均年龄为54.6岁(范围25 - 84岁)。队列中不良组织学和更晚期阶段占主导。然而,大多数(69.3%)患者接受了根治性治疗。这些患者中有52.9%接受了放疗。根治性治疗队列的5年总生存期、局部进展和远处无进展生存率分别为81.0%、95.0%和88.1%。PSM显示放疗使死亡几率降低了6.3%(匹配样本量为60,p = 0.02)。
在这项回顾性队列研究中,PSM分析后放疗对总生存期有积极影响。需要关于放疗在该疾病中作用的前瞻性数据来验证这些发现。